Intensive statin therapy for treating acute coronary syndromes

Bibliography

• Collaborative overview (‘meta-analysis’) of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. J. Cardiovasc. Risk (1999) 6(5):315-320.
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383-1389.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339(19):1349-1357.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335(14):1001-1009.
   PubMed Web of Science ®Google Scholar
• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation (1998) 97(15):1440-1445.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361(9364):1149-1158.
   PubMed Web of Science ®Google Scholar
• BAIGENT C, KEECH A, KEARNEY PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366(9493):1267-1278.
   PubMed Web of Science ®Google Scholar
• ARNTZ HR, AGRAWAL R, WUNDERLICH W et al.: Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am. J. Cardiol. (2000) 86(12):1293-1298.
   PubMed Web of Science ®Google Scholar
• LIEM AH, VAN BOVEN AJ, VEEGER NJ et al.: Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur. Heart J. (2002) 23(24):1931-1937.
   PubMed Web of Science ®Google Scholar
• OSTADAL P, ALAN D, HAJEK P et al.: Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial) [ISRCTN81331696]. Curr. Control Trials Cardiovasc. Med. (2005) 6(1):4.
   Google Scholar
• THOMPSON PL, MEREDITH I, AMERENA J, CAMPBELL TJ, SLOMAN JG, HARRIS PJ: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am. Heart J. (2004) 148(1):e2.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285(13):1711-1718.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, McCABE CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15):1495-1504.
   PubMed Web of Science ®Google Scholar
• DE LEMOS JA, BLAZING MA, WIVIOTT SD et al.: Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 292(11):1307-1316.
   PubMed Web of Science ®Google Scholar
• SCOTT WRIGHT R: The Prevention of Ischemic Events by Early Treatment of Cerivastatin Study (PRINCESS). Proceedings of the European Society of Cardiology, (2004).
   Google Scholar
• BUCHWALD H, VARCO RL, MATTS JP et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. (1990) 323(14):946-955.
   PubMed Web of Science ®Google Scholar
• OLSSON AG, SCHWARTZ GG, SZAREK M et al.: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur. Heart J. (2005) 26(9):890-896.
   PubMed Web of Science ®Google Scholar
• RAY KK, CANNON CP, McCABE CH et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. (2005) 46(8):1405-1410.
   PubMed Web of Science ®Google Scholar
• WIVIOTT SD, DE LEMOS JA, CANNON CP et al.: A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation (2006) 113(11):1406-1414.
   PubMed Web of Science ®Google Scholar
• NAGHAVI M, LIBBY P, FALK E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation (2003) 108(14):1664-1672.
   PubMed Web of Science ®Google Scholar
• NAGHAVI M, LIBBY P, FALK E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation (2003) 108(15):1772-1778.
   PubMed Web of Science ®Google Scholar
• RAY KK, CANNON CP: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol. (2005) 46(8):1425-1433.
   PubMed Web of Science ®Google Scholar
• KINLAY S, SCHWARTZ GG, OLSSON AG et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation (2003) 108(13):1560-1566.
   PubMed Web of Science ®Google Scholar
• KINLAY S, SCHWARTZ GG, OLSSON AG et al.: Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation (2004) 110(4):386-391.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. (1997) 336(14):973-979.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CANNON CP, MORROW D et al.; and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators: C-Reactive Protein Levels and Outcomes after Statin Therapy. N. Engl. J. Med. (2005) 352(1):20-28.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, MORROW DA, ROSE LM, RIFAI N, CANNON CP, BRAUNWALD E: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J. Am. Coll. Cardiol. (2005) 45(10):1644-1648.
   PubMed Web of Science ®Google Scholar
• RAY KK, CANNON CP, CAIRNS R et al.: Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. (2005) 46(8):1417-1424.
   PubMed Web of Science ®Google Scholar
• WIVIOTT SD, CANNON CP, MORROW DA, RAY KK, PFEFFER MA, BRAUNWALD E: Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol. (2005) 46(8):1411-1416.
   PubMed Web of Science ®Google Scholar
• LA ROSA J: Safety and efficacy of atorvastatin-induced very low LDL-C levels. A post hoc analysis of the TNT study. AHA Scientific Sessions, Texas, USA (2005).
   Google Scholar
• O’KEEFE JH Jr, CORDAIN L, HARRIS WH, MOE RM, VOGEL R: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol. (2004) 43(11):2142-2146.
   PubMed Web of Science ®Google Scholar
• LA ROSA JC, GRUNDY SM, WATERS DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352(14):1425-1435.
   PubMed Web of Science ®Google Scholar